TARGETING FGFR2 FUSIONS WITH NOVEL ANTIBODY THERAPEUTICS IN CHOLANGIOCARCINOMA

$238,529FY2020Defense Health AgencyDOD

The Broad Institute, Inc

Investigators

View source on USAspending →